To suggest Sarepta Therapeutics may not survive its gene therapy crisis is a sobering claim to make, STAT's Adam Feuerstein ...

Most investors don’t see the drugmaker’s executive management as credible, following the failure to disclose a patient death, ...

The crisis over Sarepta Therapeutics' Duchenne therapy offers a valuable lesson: Listening to critics, and responding with ...

Sarepta rebuffed a call from the Food and Drug Administration to halt all shipments of its gene therapy for Duchenne muscular ...

While Sarepta has now consented to the FDA’s request to stop selling Elevidys, the company’s brief standoff with the agency ...

A timeline of key developments surrounding Sarepta Therapeutics' Duchenne muscular dystrophy drug Elevidys, and the potential ...

On an investor call Friday, analysts grilled the company over its apparent lack of transparency on the matter.

There were warnings to the FDA about Sarepta Therapeutics Inc. before US regulators asked the company to halt shipments of its gene therapy.

The favorable market reaction indicates investor relief at management’s swift measures to rectify the company's worsening ...

The drastic cost-cutting move follows the deaths of two teenagers that forced the company to restrict usage of its gene ...

We believe that Sarepta Therapeutics stock, ... SRPT and S&P 500 Performance Over 2007-08 Financial Crisis. SRPT stock plummeted from from levels of about $15 in October 2007 ...

Analysts downgraded Sarepta as FDA pause on Elevidys raises regulatory uncertainty, leading to significant stock pressure and ...